Achieve Life Sciences, Inc. income statement

In fiscal 2019, Achieve Life Sciences, Inc. reported revenue of $0 and net income of −$16.4m, or −$39.76 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Achieve Life Sciences, Inc.: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019
Revenue	0	0
Research and development	6	10
General and administrative	7	7
Income before tax	−13	−16
Net income	−13	−16
Diluted EPS	−$72.29	−$39.76
Diluted shares (average)	—	—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Achieve Life Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Achieve Life Sciences, Inc.